ArticleCell2024
Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy.
Abstract read
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Mitochondrial transfer in cancer: a global bibliometric analysis.Frontiers in oncology · 2026Pooled it
- Immune regulation in mitochondrial transfer: knowledge structure and emerging trends from a bibliometric perspective.Frontiers in immunology · 2026Pooled it
- Mitochondria transfer research from cellular mechanisms to immune-inflammatory and translational frontiers: a bibliometric analysis from 2006 to 2026.Frontiers in immunology · 2026Pooled it
- Mitochondrial mechanisms underlying spatial immune phenotypes in non‑small cell lung cancer: Implications for ICI response and cold‑to‑hot tumor conversion (Review).Oncology reports · 2026Review
- Mitochondrial transfer-driven immune evasion in the tumor microenvironment.International immunology · 2026Review
- Mitochondria-Targeted Nanotherapeutics: A Promising Strategy in Modulating Mitochondrial Function, Transfer, and Transplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Targeting Metabolic Pathways to Direct T-Cell Trafficking: Therapeutic Perspectives.Biomedicines · 2026Review
- Tunneling nanotubes regulate mitochondrial homeostasis between glioblastoma and astrocytes, and between tumor cells in vivo.Nature communications · 2026Article
- CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.Blood advances · 2026Article
- Intercellular mitochondrial transfer and trans-mitophagy in response to protein import dysfunction.The Journal of cell biology · 2026Article
- Mitochondrial micro-nano reactors via enhancing mitochondrial transfer and mitophagy for alleviating metabolic crisis.Bioactive materials · 2026Article
- Article
- Regulation and function of specialized membrane protrusions in intercellular communication.Nature reviews. Molecular cell biology · 2026Review
- The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Metabolic licensing of quiescent glioblastoma activation and immune evasion via astrocyte-mitochondria shuttle.Nature communications · 2026Article
- Platelet-derived mitochondrial transfer in cancer metastasis: mechanisms, functional consequences, and translational opportunities.Clinical & experimental metastasis · 2026Review
- Myeloid cell replacement induces intercellular mitochondrial transfer and restores metabolism in a mouse model of mitochondrial disease.Nature communications · 2026Article
- Airway administered artificial mitochondria-enriched nanovesicles for efficient and selective mitochondria transfer to intervene in pulmonary fibrosis.Nature communications · 2026Article
- Spatial architecture of immunometabolism: Mitochondrial‑organelle interfaces in immune signaling (Review).International journal of molecular medicine · 2026Review
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Jeremy G BaldwinDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: jeremy.baldwin@ukr.de.
Christoph Heuser-LoyDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Tanmoy SahaCenter for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA.
Roland C SchelkerDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Dragana Slavkovic-LukicDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Nicholas StriederNext Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Inmaculada Hernandez-LopezNext Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Nisha RanaDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; University of Regensburg, Regensburg, Germany.
Markus BardenDivision of Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Fabio MastrogiovanniDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Azucena Martín-SantosDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Andrea RaimondiExperimental Imaging Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Philip BrohawnTranslational Science and Experimental Medicine, Early R&I, AstraZeneca, Gaithersburg, MD, USA.
Brandon W HiggsGenmab, Princeton, NJ, USA.
Claudia GebhardNext Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Veena KapoorCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
William G TelfordCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sanjivan GautamCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Maria XydiaBavarian Cancer Research Center (BZKF), Regensburg, Germany; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Philipp BeckhoveDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany; University of Regensburg, Regensburg, Germany; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Sina FrischholzMikrobiologisches Institut, Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
Kilian SchoberMikrobiologisches Institut, Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany; FAU Profile Center Immunomedicine, FAU Erlangen-Nürnberg, Erlangen, Germany.
Zacharias KontarakisGenome Engineering and Measurement Laboratory (GEML), ETH Zürich, Zürich, Switzerland; Functional Genomics Center Zürich, ETH Zürich, University of Zürich, Zürich 8057, Switzerland.
Jacob E CornDepartment of Biology, Institute of Molecular Health Sciences, ETH Zürich, Zürich, Switzerland.
Matteo IannaconeDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Donato InversoDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Michael RehliDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Jessica FioravantiDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shiladitya SenguptaCenter for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA. Electronic address: shiladit@mit.edu.
Luca GattinoniDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; University of Regensburg, Regensburg, Germany; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. Electronic address: luca.gattinoni@lit.eu.
Funding
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cellsR01CA293908 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Shiladitya Sengupta · 2024 to 2026
$3.5MTunneling Nanotube Inhibitors for Cancer ImmunotherapyR01CA276525 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Shiladitya Sengupta · 2023 to 2026
$3.0MMultifunctional nanoparticles for targeting aberrant tumorigenic pathwaysR01CA135242 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI SENGUPTA, SHILADITYA · 2010 to 2014
$1.8MNCI NIH HHS R01 CA135242NCI NIH HHS R01 CA276525NCI NIH HHS R01 CA293908
Abstract
Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular connections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria into CD8
Indexed as
CD8-Positive T-LymphocytesMice, Inbred C57BLMitochondriaNanotubesAnimalsCell Line, TumorFemaleHumansMesenchymal Stem CellsMiceNeoplasmsbone marrow stromal cellscancer immunotherapyCAR T therapyCD8(+) T cellsimmune metabolismmitochondrial transfernanotubesTalin 2TCR-T therapyTIL therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.